[HTML][HTML] Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

FX Lescure, H Honda, RA Fowler, JS Lazar… - The Lancet …, 2021 - thelancet.com
Background Elevated proinflammatory cytokines are associated with greater COVID-19 severity.
We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, …

[HTML][HTML] Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3 …

…, D Lebeaux, B Lefevre, S Leroy, FX Lescure… - The Lancet infectious …, 2022 - thelancet.com
Background The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversial.
We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with …

Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound?

…, D Slama, C Joseph, A Lemaignen, FX Lescure… - Journal of Infection, 2020 - Elsevier
For the first 3 months of COVID-19 pandemic, COVID-19 was expected to be an immunizing
non-relapsing disease. We report a national case series of 11 virologically-confirmed COVID…

[PDF][PDF] Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia

…, J Fouret, J Dubois, A Gaymard, FX Lescure… - Cell Reports …, 2020 - cell.com
In the current COVID-19 pandemic context, proposing and validating effective treatments
represents a major challenge. However, the scarcity of biologically relevant pre-clinical models …

[HTML][HTML] Clinical and virological data of the first cases of COVID-19 in Europe: a case series

FX Lescure, L Bouadma, D Nguyen… - The Lancet Infectious …, 2020 - thelancet.com
Background On Dec 31, 2019, China reported a cluster of cases of pneumonia in people at
Wuhan, Hubei Province. The responsible pathogen is a novel coronavirus, named severe …

[HTML][HTML] Compassionate use of remdesivir for patients with severe Covid-19

…, T Feldt, G Green, ML Green, FX Lescure… - … England Journal of …, 2020 - Mass Medical Soc
Background Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases,
has shown in vitro activity against SARS-CoV-2. Methods We provided remdesivir on a …

Type 1 interferons as a potential treatment against COVID-19

E Sallard, FX Lescure, Y Yazdanpanah, F Mentre… - Antiviral research, 2020 - Elsevier
Type 1 interferons have a broad antiviral activity in vitro and are currently evaluated in a
clinical trial to treat MERS-CoV. In this review, we discuss preliminary data concerning the …

[HTML][HTML] First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020

…, S Ismael, D Nguyen, D Malvy, FX Lescure… - …, 2020 - eurosurveillance.org
A novel coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) causing
a cluster of respiratory infections (coronavirus disease 2019, COVID-19) in Wuhan, China, …

Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data

…, E Fois, R Lepeule, TA Szwebel, FX Lescure… - Bmj, 2020 - bmj.com
Objective To assess the effectiveness of hydroxychloroquine in patients admitted to hospital
with coronavirus disease 2019 (covid-19) pneumonia who require oxygen. Design …

Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort

…, B Montes, K Bouiller, FX Lescure… - Proceedings of the …, 2021 - National Acad Sciences
The characterization of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral
kinetics in hospitalized patients and its association with mortality is unknown. We analyzed …